Loader

Pathways

PathWhiz ID Pathway Meta Data

PW000125

Pw000125 View Pathway
drug action

Piroxicam Action Pathway

Homo sapiens
Piroxicam (also named Feldene or Piroxicamum) is a nonsteroidal anti-inflammatory drug. Piroxicam can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of piroxicam. Piroxicam can prevent movement of leukocytes to inflammation site so that thromboxane A2 can't be produced.

PW122326

Pw122326 View Pathway
drug action

Piroxicam Action Action Pathway Xuan (Demo Purpose) 2

Homo sapiens

PW122274

Pw122274 View Pathway
drug action

Piroxicam Action Action Pathway Xuan (Demo Purpose)

Homo sapiens

PW122252

Pw122252 View Pathway
drug action

Piroxicam Action Action Pathway Xuan

Homo sapiens
Piroxicam is a nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects. Piroxicam will be transported via Solute carrier family 22 member 6, Solute carrier family 22 member 8, Solute carrier family 22 member 11 and Solute carrier organic anion transporter family member 2B1 into cell. After get into cell, piroxicam will inhibit the Prostaglandin G/H synthase 2 and Prostaglandin G/H synthase 1's function; so that Prostaglandin G2 couldn't be transferred into Prostaglandin H2.

PW176399

Pw176399 View Pathway
metabolic

Piritramide Predicted Metabolism Pathway

Homo sapiens
Metabolites of Piritramide are predicted with biotransformer.

PW128420

Pw128420 View Pathway
drug action

Piritramide Opioid Agonist Action Pathway

Homo sapiens
Piritramide is an opioid analgesic used to treat severe pain. It is under investigation for the treatment of colon cancer and minimal residual disease. Piritramide binds to mu, kappa, and delta opioid receptors on presynaptic neuron membranes, stimulating the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids close N-type voltage-operated calcium channels and open calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization and reduced neuronal excitability. Morphine acts at A delta and C pain fibres in the dorsal horn of the spinal cord. By decreasing neurotransmitter action there is less pain transmittance into the spinal cord. This leads to less pain perception.

PW146535

Pw146535 View Pathway
drug action

Piritramide Drug Metabolism Action Pathway

Homo sapiens

PW176227

Pw176227 View Pathway
metabolic

Pirfenidone Predicted Metabolism Pathway

Homo sapiens
Metabolites of Pirfenidone are predicted with biotransformer.

PW145620

Pw145620 View Pathway
drug action

Pirfenidone Drug Metabolism Action Pathway

Homo sapiens

PW145519

Pw145519 View Pathway
drug action

Piretanide Drug Metabolism Action Pathway

Homo sapiens